Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Predictive value of the ThroLy score in Hodgkin lymphoma

Darko Antic, MD, PhD, University of Belgrade, School of Medicine, Belgrade, Serbia, gives an overview of the Thrombosis Lymphoma (ThroLy) score, which was developed as a risk assessment model for calculating the risk of thromboembolism in patients with lymphoma. The ThroLy score has been validated in serval studies, predominantly in patients with non-Hodgkin lymphoma. Dr Antic presents data from a study analysing and validating the ThroLy score in patients with Hodgkin lymphoma. This study, which incorporated data from 5509 newly diagnosed patients with Hodgkin lymphoma from the German Hodgkin Study Group, reported that the ThroLy score had a sensitivity of 49%, a specificity of 65%, and negative and positive predictive values of 95% and 97% respectively. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.


Darko Antic, MD, PhD, has received honoraria from Roche, Sandoz, Takeda and Johnson & Johnson.